Sheriene Moussa Afify

Sheriene Moussa Afify

Auto-generated profile, based on publicly available information

Sheriene Moussa Afify

University of Veterinary Medicine Vienna Messerli-Research-Institute

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2020 in Allergy
Verified
Journal Article
Open access
PDF file
KHKarin Hufnagl
Karin Hufnagl
SASheriene Moussa Afify
Sheriene Moussa Afify
NBNina Braun
Nina Braun
SWStefanie Wagner
Stefanie Wagner
MWMichael Wallner
Michael Wallner
EJErika Jensen-Jarolim
Erika Jensen-Jarolim
Click on the article title to read more.

26 May 2021 in Allergy
Verified
Journal Article
Open access
PDF file
LPLisa‐Marie Petje
Lisa‐Marie Petje
SJSebastian A. Jensen
Sebastian A. Jensen
SSSebastian Szikora
Sebastian Szikora
MSMartin Sulzbacher
Martin Sulzbacher
TBTina Bartosik
Tina Bartosik
Franziska Roth-WalterFranziska Roth-Walter
Franziska Roth-Walter
Click on the article title to read more.

12 February 2022 in Clinical and Translational Allergy
Verified
Journal Article
Open access
PDF file
IPIsabella Pali-Schöll
Isabella Pali-Schöll
Rodolfo BianchiniRodolfo Bianchini
Rodolfo Bianchini
SASheriene Moussa Afify
Sheriene Moussa Afify
GHGerlinde Hofstetter
Gerlinde Hofstetter
SWSimona Winkler
Simona Winkler
EJErika Jensen-Jarolim
Erika Jensen-Jarolim
Background: Growing up on a cattle farm and consuming raw cow's milk protects against asthma and allergies. We expect a cattle‐specific protein as active component in this farm effect.Methods: Dust was collected from cattle and poultry stables and from mattresses of households. Urine was obtained from cattle, and ambient aerosols were sampled. Samples were analysed for BLG by SDS PAGE/immunoblot and mass spectrometry, and for association with metals by SEC‐ICP‐MS. PBMC of healthy donors were incubated with BLG +/− zinc, and proliferation and cytokines determined. BALB/c mice were pre‐treated intranasally with stable dust extract containing BLG or depleted of BLG, and subsequent allergy response after sensitization was evaluated on antibody and symptom level.Results: A major protein in dust from cattle farms and ambient air was identified as BLG. Urine from female and male cattle is a major source of BLG. In dust samples, BLG was associated with zinc. In vitro, zinc‐BLG provoked significantly lower proliferation of CD4+ and CD8+ cells while inducing significantly higher levels of IFN‐γ and IL‐6 than the apo‐BLG devoid of zinc. In vivo, pre‐treatment of mice with dust extract containing BLG resulted in lower allergy symptom scores to BLG and unrelated Bet v 1 than pre‐treatment with extract depleted of BLG. These in vitro and in vivo effects were independent of endotoxin.Conclusion: The lipocalin BLG is found in large amounts in cattle urine, accumulates in bovine dust samples and is aerosolized around farms. Its association with zinc favorably shapes the human cellular immune response towards Th1‐cytokines in vitro. BLG together with zinc in stable dust protects mice from allergic sensitization. BLG with its associated ligands may in an innate manner contribute to the allergy‐protective farm effect.

13 November 2021 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
PDF file
SASheriene Moussa Afify
Sheriene Moussa Afify
ARAndreas Regner
Andreas Regner
LPLuis F. Pacios
Luis F. Pacios
BBBart R. Blokhuis
Bart R. Blokhuis
SJSebastian A. Jensen
Sebastian A. Jensen
Franziska Roth-WalterFranziska Roth-Walter
Franziska Roth-Walter
Background: Previously, the protective farm effect was imitated using the whey protein beta‐lactoglobulin (BLG) that is spiked with iron‐flavonoid complexes. Here, we formulated for clinical translation a lozenge as food for special medical purposes (FSMP) using catechin‐iron complexes as ligands for BLG. The lozenge was tested in vitro and in a therapeutical BALB/c mice model. Methods: Binding of iron‐catechin into BLG was confirmed by spectroscopy and docking calculations. Serum IgE binding of children allergic or tolerating milk was assessed to loaded (holo‐) versus empty (apo‐) BLG and for human mast cell degranulation. BLG and Bet v 1 double‐sensitized mice were orally treated with the holoBLG or placebo lozenge, and immunologically analysed after systemic allergen challenge. Human PBMCs of pollen allergic subjects were flow cytometrically assessed after stimulation with apoBLG or holoBLG using catechin‐iron complexes as ligands. Results: One major IgE and T cell epitope were masked by catechin‐iron complexes, which impaired IgE binding of milk‐allergic children and degranulation of mast cells. In mice, only supplementation with the holoBLG lozenge reduced clinical reactivity to BLG and Bet v 1, promoted Tregs, and suppressed antigen presentation. In allergic subjects, stimulation of PBMCs with holoBLG led to a significant increase of intracellular iron in circulating CD14+ cells with significantly lower expression of HLADR and CD86 compared to their stimulation with apoBLG. Conclusion: The FSMP lozenge targeted antigen presenting cells and dampened immune activation in human immune cells and allergic mice in an antigen‐non‐specific manner, thereby conferring immune resilience against allergic symptoms.

14 August 2021 in Allergy
Verified
Journal Article
Open access
PDF file
KHKarin Hufnagl
Karin Hufnagl
LKLivia Kromp
Livia Kromp
Rodolfo BianchiniRodolfo Bianchini
Rodolfo Bianchini
SASheriene Moussa Afify
Sheriene Moussa Afify
MWMarkus Wiederstein
Markus Wiederstein
EJErika Jensen-Jarolim
Erika Jensen-Jarolim
Click on the article title to read more.

30 January 2024
Verified
Preprint
Open access
SASheriene Afify
Sheriene Afify
ARAndreas Regner
Andreas Regner
LPLuis Pacios
Luis Pacios
BBBart Blokhuis
Bart Blokhuis
SJSebastian Jensen
Sebastian Jensen
FRFranziska Roth-Walter
Franziska Roth-Walter
Background: We previously proposed the whey protein beta-lactoglobulin (BLG) loaded with iron-siderophore complexes as the active principle in the farm protective effect against allergies. A lozenge as food for specific medical purposes (FSMP) was formulated to assess its therapeutical efficacy in BALB/c mice and in-vitro experiments. Methods: Binding of iron-catechin into BLG was confirmed by spectroscopy and docking calculations. Serum IgE binding of children allergic to milk, or tolerating milk, was assessed to loaded (holo-) versus empty (apo-) BLG and for human mast cell degranulation. BLG and Bet v 1 double-sensitized mice were orally treated with the lozenge or placebo, and immunologically analysed after systemic allergen challenge. Human PBMCs of pollen allergic subjects were flow cytometrically assessed after stimulation with holoBLG in conjugation with catechin-iron complexes as ligands in a dietary supplement or with the apoBLG. Results: One major IgE- and T cell epitope were masked by catechin-iron complexes, which impaired IgE binding of milk allergic children and degranulation of mast cells. In mice, only supplementation with the lozenge reduced clinical reactivity to BLG and Bet v 1, promoted Tregs, and suppressed antigen presentation. In allergic subjects, stimulation of PBMCs with holoBLG led to a significant increase of intracellular iron in circulating CD14+ cells with significantly lower expression of HLADR and CD86 compared to their stimulation with apoBLG. Conclusion: The FSMP lozenge targeted antigen presenting cells and dampened immune activation in human immune cells and allergic mice in an antigen nonspecific manner, thereby conferring immune resilience against allergic symptoms.